The global desiccant closures market is projected to increase from USD 538.4 million in 2026 to USD 937.2 million by 2036, registering a 5.7% CAGR during the 2026 to 2036 forecast period, according to Future Market Insights (FMI). Demand is being supported by moisture-sensitive oral medicines that require protection after repeated bottle opening, while regulatory attention is placing greater emphasis on the complete container-closure system.
In August 2026, the U.S. Food and Drug Administration issued draft guidance treating container-closure quality as a complete package-system question rather than assessing individual components in isolation. The approach makes bottle fit, stability evidence and filling-line performance relevant when pharmaceutical manufacturers evaluate integrated closure systems.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-35041
Global Segment Leaders
- Screw closures — 32.0%: Familiar threaded neck interfaces support repeated opening and reclosure.
- Polymer systems — 29.0%: Molded structures can retain active moisture-control material within the closure.
- Child-resistant — 29.0%: Safety requirements combine access control with moisture protection on reclosable packs.
- Retail pharmacy — 30.0%: Multidose bottles face repeated ambient exposure after dispensing.
- Sales channel: The supplied report content identifies direct pharma contracts, specialty distributors and online B2B, but does not disclose a leading sales-channel share.
Screw closures are estimated to hold 32.0% of the product-type segment in 2026. The report attributes their position to familiar bottle-neck interfaces and the ability to incorporate moisture protection and safety features without requiring a complete reconstruction of standard capping arrangements.
Polymer systems are projected to account for 29.0% of the material segment. Their molded geometry allows closure manufacturers to integrate protected active-material chambers while maintaining sealing and reclosure functions. Aptar CSP Technologies stated in June 2026 that its N-Sorb supports bottle formats and other active-packaging configurations following USPTO allowance.
Child-resistant formats are expected to capture 29.0% of the compliance-feature segment in 2026. Sanner’s May 2025 TabTec CR launch combined certified push-and-flip safety with integrated desiccant protection for oral-solid doses.
Retail pharmacy represents the leading disclosed end-use segment at 30.0% in 2026. NHSBSA reported in June 2026 that England dispensed 1.30 billion community prescription items during 2025/26, maintaining the commercial relevance of reliable reclosure for multidose oral medicines.
Country-Level Performance
Country | CAGR | Key Growth Driver
- UAE | 7.1% | Emirates Drug Establishment’s directory recorded a UAE-manufactured VONACAB 20 mg tablet registration dated May 26, 2025, supporting new primary-packaging decisions.
- Saudi Arabia | 6.8% | SFDA reported in January 2026 that the drug sector included 9 licensed factories and 568 warehouses during 2025.
- South Korea | 6.5% | MFDS documented in December 2025 that 45 unapproved overseas medical products received emergency introduction during the year, including 15 medicines.
- USA | 6.2% | FDA reported in 2026 that CDER approved 46 novel drugs during the 2025 calendar year.
- Germany | 5.9% | ABDA reported in January 2026 that Germany ended 2025 with 16,601 pharmacies after 502 closures and 62 openings.
- UK | 5.6% | NHSBSA reported in October 2025 that 10,407 community pharmacies were open in England as of March 31, 2025.
- France | 5.3% | The National Council of the Order of Pharmacists stated in March 2025 that DP-Ruptures linked 99% of pharmacies with manufacturers producing more than 84% of medicines available in France.
- Japan | 4.9% | Japan’s Ministry of Health, Labour and Welfare reported in August 2026 that written information accompanied 76.7% of in-store category-one OTC medicine sales in its latest survey.
Regional Context
The UAE and Saudi Arabia form the faster-growing country tier, with CAGRs of 7.1% and 6.8%, respectively. The report links UAE growth to a changing registration base and Saudi expansion to increasing local pharmaceutical production and warehouse capacity, creating more packaging qualification activity.
South Korea and the USA follow at 6.5% and 6.2%. Rapid product access and pharmaceutical turnover create opportunities for new closure qualification before packaging specifications become fixed in long-term stability records.
Germany, the UK and France occupy the middle tier, with CAGRs ranging from 5.9% to 5.3%. Mature pharmacy and pharmaceutical systems support continued demand, but established packaging specifications and post-approval change requirements can slow closure conversion.
Japan, at 4.9%, represents the lowest CAGR among the profiled countries. The report associates the mature market with conservative packaging changes and greater attention to usability on repeatedly opened oral-solid medicine packs.
The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with the full country scope extending across more than 25 additional countries beyond the specifically profiled markets.
Competitive Landscape
The competitive landscape includes Sanner, Colorcon, Aptar CSP Technologies, Xinfuda Medical Packaging, ALPLApharma, Gerresheimer, West Pharmaceutical Services, and Amcor. Sanner, Colorcon, Aptar CSP Technologies and Xinfuda Medical Packaging are profiled for direct active moisture-protection capabilities, while ALPLApharma and Gerresheimer participate across pharmaceutical container-and-closure platforms. West Pharmaceutical Services and Amcor operate across adjacent regulated closure and healthcare packaging interfaces.
Recent developments include Xinfuda Medical Packaging’s GMP upgrade project announced in June 2025, undertaken ahead of tighter production requirements for pharmaceutical packaging materials. In January 2025, West Pharmaceutical Services introduced Daikyo PLASCAP RUV closures in a nested ready-to-use format for pharmaceutical fill-finish lines. Amcor also completed its combination with Berry Global in April 2025, broadening the group’s healthcare containers-and-closures manufacturing base.
The market’s principal driver is the need to protect moisture-sensitive tablets and capsules after patients begin repeatedly opening multidose bottles. At the same time, closure conversion can require fresh stability studies and line trials because the closure forms part of the qualified primary package. The report identifies integrated desiccant and safety functions as an opportunity to combine moisture control with other packaging requirements once the complete package passes line and stability qualification.
Explore In-Depth Analysis—Click Here to Access the Report!
https://www.futuremarketinsights.com/reports/desiccant-closures-market
About Report
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including pharmaceuticals, packaging, and healthcare.
Related Report Links:
FMI Custom Research: Strategic Intelligence for Confident Decision-Making
In today’s rapidly evolving business environment, leadership teams need more than market data—they need clear, actionable intelligence tailored to their strategic objectives. FMI’s Custom Research solutions are designed around the specific business questions organizations need answered, enabling executives to evaluate growth opportunities, validate investments, assess competitive dynamics, and reduce uncertainty before making critical decisions. By combining deep industry expertise, primary research, and proprietary market intelligence, FMI delivers insights that help organizations move from assumptions to evidence-based strategies with greater speed and confidence.
Business Impact
FMI helps organizations transform market complexity into strategic clarity, enabling leadership teams to identify growth opportunities faster, optimize resource allocation, strengthen competitive positioning, and make high-stakes business decisions with confidence.
To explore how FMI Custom Research can support your strategic priorities, please connect with our team at – sales@futuremarketinsights.com
About Future Market Insights (FMI)
Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
